Hubei Goto Biopharm Co.,Ltd. (SHE:300966)
China · Delayed Price · Currency is CNY 21.58
+0.25 (1.17%)
Jan 23, 2026, 3:04 PM CST
Hubei Goto Biopharm Revenue
Hubei Goto Biopharm had revenue of 152.67M CNY in the quarter ending September 30, 2025, with 16.04% growth. This brings the company's revenue in the last twelve months to 626.28M, up 14.55% year-over-year. In the year 2024, Hubei Goto Biopharm had annual revenue of 536.60M, down -5.26%.
Revenue (ttm)
626.28M
Revenue Growth
+14.55%
P/S Ratio
3.97
Revenue / Employee
766.56K
Employees
817
Market Cap
2.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 536.60M | -29.80M | -5.26% |
| Dec 31, 2023 | 566.40M | -38.17M | -6.31% |
| Jan 1, 2023 | 604.57M | 13.69M | 2.32% |
| Jan 1, 2022 | 590.89M | 122.77M | 26.23% |
| Dec 31, 2020 | 468.12M | 3.32M | 0.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Jiangsu Sihuan Bioengineering | 341.90M |
| Sailong Pharmaceutical Group | 244.84M |
| Shanghai Serum Bio-Technology | 196.76M |